Compare Ascendis Pharma A/S (ASND) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs General Mills, Inc. — how do they compare? Ascendis Pharma A/S trades at $263.66 (market cap $17.74B), while General Mills, Inc. trades at $37.02 (market cap $19.33B). The key difference: Ascendis Pharma A/S and General Mills, Inc. are close in size by market cap, and General Mills, Inc. pays a 6.74% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GIS | |
|---|---|---|
Market Cap | $17.74B | $19.33B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $51.60 |
52-Week Low | $163.32 | $32.17 |
Enterprise Value | $18.11B | $32.82B |
Dividend Yield | — | 6.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
General Mills (GIS) trades at $36.22, up 1.03% on the day, near the analyst consensus price target of $36.14. The stock presents a mixed picture with a low P/E of 9.23 suggesting value, but profitability metrics like a negative net income margin and ROE for 2026 signal challenges. Recent Q2 2026 earnings beat expectations, yet the technical outlook is bearish, and news highlights sales pressure and a focus on cost savings to drive a margin recovery in fiscal 2027.
The investment outlook is cautious. The stock's low valuation and dividend yield offer potential value, but persistent sales softness, margin pressure from competition, and a high debt-to-asset ratio of 45% pose significant risks. Analyst sentiment is predominantly neutral to negative, with a majority hold rating, indicating a wait-and-see approach is warranted until clearer signs of sustainable growth emerge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
